Incidence and Clinicopathological Features of Breast Cancer in the Northern Emirates: Experience from Sharjah Breast Care Center

Figures & data

Table 1 Crude and Age-Standardized Incidence Rate

Age Group (Years)	Breast Cancer	Age-Specific Incidence (per 10^5 Years)	World Age-Standardized Incidence Rate X 100,000 (W-ASIR)
10–19	0	0	0
20–29	0	0	0
30–39	16	2.08	0.14
40–49	33	13.69	0.82
50–59	24	25.89	1.16
≥60	21	67.98	2.37
Total	94		4.51

Table 2 Comparison of Clinical Characteristics of Malignant and Benign Cases

	Total (n=1048)	Malignant (n=94)	Benign (n=954)	P-value
Demographic data
Age at diagnosis, mean (SD), years	46 (11)	51 (12)	46 (11)	<0.001
Age n (%) years
<40	267 (25)	16 (17)	251 (26)
40–49	405 (39)	33 (35)	373 (39)
50–59	251 (24)	24 (25)	225 (24)
≥60	125 (12)	21 (22)	105 (11)	<0.001
Physical examination
Height, mean (SD)	159.46 (6)	159.77 (6)	157.85 (6)	0.011
Weight [kg], mean (SD)	74.37 (16)	76.73 (14)	73.93 (16)	0.127
BMI, n (%)
Normal (18.5–24.9)	694 (66)	27 (29)	664 (70)	<0.001
Overweight (25 −30)	173 (16)	27 (29)	146 (15)
Obese >30	185 (18)	40 (43)	144 (15)
Menopause, n (%)	350 (34)	45 (48)	305 (33)	0.004
Laboratory data
Serum 25(OH)D, mean (SD), ng/mL	19.57 (10)	16.41 (10)	21.16 (10)	0.015

Figure 1 Serum 25(OH)D level between benign and malignant cases.

Table 3 Association Between Serum 25(OH)D Levels and Breast Cancer Risk

Variables	Crude OR (95% CI)	**Adjusted OR (95% CI)	P-value	Bootstrap (95% BootCI)
Vitamin D deficiency*	10.19 (5.94–17.49)	4.63 (2.61–8.23)	<0.001	(2.20–7.67)

Notes: *Vitamin D deficiency is defined as serum 25(OH)D levels lower than 20 ng/mL; **Adjusted for age, menopausal status and BMI.

Abbreviation: OR, odd ratio.

Table 4 Clinicopathological Characteristics of Malignant Cases

	Malignant (n=94)
Type of breast cancer, n (%)
IDC	79 (84)
ILC	5 (5)
Mixed IDC and ILC	5 (5)
Mucinous carcinoma	3 (3)
Ductal carcinoma in situ	1 (1)
Mammary carcinoma	1 (1)
Molecular subtype of breast cancer, n (%)
Luminal A*	34 (36)
Luminal B (HER2-)**	13 (14)
Triple positive	15(16)
HER2-enriched	4 (4)
Basal-like subtypes	12 (13)
Receptor status, n (%)
ER	61 (65)
PR	57 (61)
HER2***	19 (20)
Ki67****	29 (31)
E-cadherin	11 (12)
Tumor location, n (%)
Left	57 (61)
Right	34 (36)
Bilateral	3 (3)
Tumor size, mean (SD), cm	2.40 (2)

Notes: *Ki67 was defined as Immunoreactive in > or =14% in malignant cells; **Luminal A was defined as ER and/or PR positive, ki67 low (<14%); ***Luminal B was defined as ER and/or PR positive, ki67 high (>14%); ****HER2 expressing tumor (3+ by immunohistochemistry (IHC) or by fluorescence in situ hybridization (FISH)).

Figure 2 Age difference among different breast cancer molecular subtypes.